Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Minimally invasive classification of paediatric solid tumours using reduced representation bisulphite sequencing of cell-free DNA: a proof-of-principle study.
Van Paemel R, De Koker A, Vandeputte C, van Zogchel L, Lammens T, Laureys G, Vandesompele J, Schleiermacher G, Chicard M, Van Roy N, Vicha A, Tytgat GAM, Callewaert N, De Preter K, De Wilde B. Van Paemel R, et al. Epigenetics. 2021 Jan-Feb;16(2):196-208. doi: 10.1080/15592294.2020.1790950. Epub 2020 Jul 14. Epigenetics. 2021. PMID: 32662719 Free PMC article.
Specific and Sensitive Detection of Neuroblastoma mRNA Markers by Multiplex RT-qPCR.
van Zogchel LMJ, Zappeij-Kannegieter L, Javadi A, Lugtigheid M, Gelineau NU, Lak NSM, Zwijnenburg DA, Koster J, Stutterheim J, van der Schoot CE, Tytgat GAM. van Zogchel LMJ, et al. Cancers (Basel). 2021 Jan 5;13(1):150. doi: 10.3390/cancers13010150. Cancers (Basel). 2021. PMID: 33466359 Free PMC article.
Mesenchymal Neuroblastoma Cells Are Undetected by Current mRNA Marker Panels: The Development of a Specific Neuroblastoma Mesenchymal Minimal Residual Disease Panel.
van Wezel EM, van Zogchel LMJ, van Wijk J, Timmerman I, Vo NK, Zappeij-Kannegieter L, deCarolis B, Simon T, van Noesel MM, Molenaar JJ, van Groningen T, Versteeg R, Caron HN, van der Schoot CE, Koster J, van Nes J, Tytgat GAM. van Wezel EM, et al. Among authors: van wijk j, van noesel mm, van der schoot ce, van zogchel lmj, van groningen t, van nes j. JCO Precis Oncol. 2019 Oct 3;3:PO.18.00413. doi: 10.1200/PO.18.00413. eCollection 2019. JCO Precis Oncol. 2019. PMID: 34036221 Free PMC article.
G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment.
Martinez Sanz P, van Rees DJ, van Zogchel LMJ, Klein B, Bouti P, Olsman H, Schornagel K, Kok I, Sunak A, Leeuwenburg K, Timmerman I, Dierselhuis MP, Kholosy WM, Molenaar JJ, van Bruggen R, van den Berg TK, Kuijpers TW, Matlung HL, Tytgat GAM, Franke K. Martinez Sanz P, et al. Among authors: van zogchel lmj. J Immunother Cancer. 2021 May;9(5):e002259. doi: 10.1136/jitc-2020-002259. J Immunother Cancer. 2021. PMID: 34049929 Free PMC article.
Improving Risk Stratification for Pediatric Patients with Rhabdomyosarcoma by Molecular Detection of Disseminated Disease.
Lak NSM, Voormanns TL, Zappeij-Kannegieter L, van Zogchel LMJ, Fiocco M, van Noesel MM, Merks JHM, van der Schoot CE, Tytgat GAM, Stutterheim J. Lak NSM, et al. Among authors: van zogchel lmj. Clin Cancer Res. 2021 Oct 15;27(20):5576-5585. doi: 10.1158/1078-0432.CCR-21-1083. Epub 2021 Jul 20. Clin Cancer Res. 2021. PMID: 34285060 Free PMC article.
15 results